Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

European Journal of Clinical Pharmacology

Volumn 55, Issue 9, 1999, Pages 633-637

  Burnier, M ^a   Fricker, A F ^a   Hayoz, D ^a   Nussberger, J ^a   Brunner, H R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Receptor antagonist; Vasopressin; YM087

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL PHARMACOLOGY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ELECTROLYTE BALANCE; FLUID BALANCE; GLYCOGENOLYSIS; HUMAN; HUMAN EXPERIMENT; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA OSMOLALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; SKIN BLOOD VESSEL; THROMBOCYTE AGGREGATION; URINE FLOW RATE; URINE OSMOLALITY; UTERUS CONTRACTILITY; VASOCONSTRICTION; VASOPRESSIN BLOOD LEVEL;

EID: 0032755612     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050685     Document Type: Article

References (20)

1. 1. Jard S, Elands J, Schmidt A, Barberis C (1988) Vasopressin and oxytocin receptors: an overview. In: Imura H, Shizurne K (eds) Progress in endocrinology. Excerpta Medica, Amsterdam, pp 1183-1188
2. 2. Laszlo FA, Laszlo F, De Vied D (1991) Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43: 73-108
3. 3. Mah SC, Hofbauer KG (1987) Antagonists of arginine-vasopressin: experimental and clinical applications. Drugs Future 12: 1055-1070
4. 1 receptor antagonist. Science 252: 572-574
5. 2 receptor antagonist. Br J Pharmacol 105: 787-791
6. 1a receptors. J Clin Invest 92: 224-231
7. 2 receptor antagonist. J Clin Invest 98: 2729-2738
8. 8. Kamoi K (1997) Syndrome of inappropriate antidiuresis without involving inappropriate secretion of vasopressin in an elderly woman: effect of intravenous administration of the nonpeptide vasopressin V2 receptor antagonist OPC-31260. Nephron 76: 111-115
9. 9. Mimura Y, Ogura T, Hayakawa N, Otsuka F, Hashimoto M, Yamauchi T, Makino H, Ogawa N (1997) In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260. Nephron 76: 331-336
10. 10. Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI (1994) Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertnsion in the rat. Hypertension 23: 737-743
11. 11. Burrell LM, Risvanis J, Phillips PA, Naitoh M, Johnston CI (1997) Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension. Clin Exp Hypertens 19: 981-991
12. 12. Naitoh M, Burrell LM, Risvanis J, Aldred KL, Rockell MD, Johnston CI, Phillips PA (1997) Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR. Am J Physiol 272: F229-F234
13. 13. Bossmar T, Brouard R, Doberl A, Akerlund M (1997) Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions. Br J Obstet Gynaecol 104: 471-477
14. 1 receptor antagonist on the vasopressin-induced vasoconstriction in humans. Hypertension 30: 1121-1127
15. 15. Matsuhisa A, Tanaka A, Kikuchi K, Shimada Y, Yatsu T, Yanagisawa I (1997) Nonpeptide arginine vasopressin antagonists for both V1a and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4′[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide derivatives. Chem Pharm Bull 45: 1870-1874
16. 16. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A (1998) Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1a and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 357: 63-69
17. 17. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A (1998) Binding characteristics of YM087, an AVP-receptor antagonist, in rhesus monkey liver and kidney membranes. Peptides 19: 691-696
18. 18. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Takanashi M, Yatsu T, Uchida W, Tanaka A (1997) Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282: 301-308
19. 19. Yatsu T, Tomura Y, Tahara A, Wada K, Tsukada J, Uchida W, Tanaka A, Takenada T (1997) Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur J Pharmacol 321: 225-230
20. 20. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A (1997) Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol 30: 759-766